Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Rochal Technologies LLC has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, meaning each pending case is being handled by a different individual. Furthermore, the portfolio involves 3 distinct art units, indicating that each of the 3 pending office actions falls into a different technical sub-category within the biotechnology field.
KOMATSU, LI N is the busiest examiner, though they are responsible for only 1 busiest examiner pending action. This figure is consistent with the total count of 3 distinct examiners for the 3 pending office actions. The lack of overlap between examiners and art units suggests that the company is pursuing distinct technical paths. Success in these 3 pending office actions will require tailored arguments for each of the 3 distinct examiners across the 3 distinct art units involved in the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19371959 | HYDROLYZED COLLAGEN COMPOSITIONS WITH ANTIBIOTICS AND METHODS OF USING THE SAME | PARK, HAEJIN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19422266 | HYDROXYPROLINE-FREE HYDROLYZED COLLAGEN PEPTIDES AND METHODS OF MAKING AND USING THE SAME | KOMATSU, LI N | — |
| 19371959 | HYDROLYZED COLLAGEN COMPOSITIONS WITH ANTIBIOTICS AND METHODS OF USING THE SAME | PARK, HAEJIN S | — |
| 19328859 | ANTIMICROBIAL HYDROLYZED COLLAGEN WITH POLYLYSINE AND METHODS OF USING THE SAME | BOWLES, DAVID PAUL | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1614 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19422266 | HYDROXYPROLINE-FREE HYDROLYZED COLLAGEN PEPTIDES AND METHODS OF MAKING AND USING THE SAME | KOMATSU, LI N | 1658 | §102 | Non-Final OA | — | Pending | Dec 16, 2025 |
| 19371959 | HYDROLYZED COLLAGEN COMPOSITIONS WITH ANTIBIOTICS AND METHODS OF USING THE SAME | PARK, HAEJIN S | 1614 | §102§103 | Non-Final OA | — | Pending | Oct 28, 2025 |
| 19328859 | ANTIMICROBIAL HYDROLYZED COLLAGEN WITH POLYLYSINE AND METHODS OF USING THE SAME | BOWLES, DAVID PAUL | 1654 | §103 | Non-Final OA | — | Pending | Sep 15, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRochal Technologies LLC has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Li N Komatsu has the most, with 1 of Rochal Technologies LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
